000 01535 a2200409 4500
005 20250514062946.0
264 0 _c20031120
008 200311s 0 0 eng d
022 _a0143-4004
024 7 _a10.1053/plac.2002.0917
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMartel, F
245 0 0 _aUptake of 1-methyl-4-phenylpyridinium (MPP+) by the JAR human placental choriocarcinoma cell line: comparison with 5-hydroxytryptamine.
_h[electronic resource]
260 _bPlacenta
_cApr 2003
300 _a361-9 p.
_bdigital
500 _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _a1-Methyl-4-phenylpyridinium
_xmetabolism
650 0 4 _aCarrier Proteins
_xmetabolism
650 0 4 _aCell Line, Tumor
650 0 4 _aChoriocarcinoma
_xmetabolism
650 0 4 _aDesipramine
_xpharmacology
650 0 4 _aDose-Response Relationship, Drug
650 0 4 _aFemale
650 0 4 _aFluoxetine
_xpharmacology
650 0 4 _aHumans
650 0 4 _aMembrane Glycoproteins
_xmetabolism
650 0 4 _aMembrane Transport Proteins
650 0 4 _aNerve Tissue Proteins
650 0 4 _aPlacenta
_xdrug effects
650 0 4 _aQuinolinium Compounds
_xpharmacology
650 0 4 _aSerotonin
_xmetabolism
650 0 4 _aSerotonin Plasma Membrane Transport Proteins
650 0 4 _aUterine Neoplasms
_xmetabolism
700 1 _aKeating, E
773 0 _tPlacenta
_gvol. 24
_gno. 4
_gp. 361-9
856 4 0 _uhttps://doi.org/10.1053/plac.2002.0917
_zAvailable from publisher's website
999 _c12451166
_d12451166